#USA #Sheridan #Body Composition #Zyndio #DEXASCAN

Collaboration Between Zyndio and DEXASCAN

Zyndio, a health technology innovator, has joined forces with DEXASCAN, a leading provider of body composition testing. This strategic partnership introduces a new program called From Scan to Plan, developed to seamlessly integrate diagnostic measurements with physician-led care. By merging Zyndio's telehealth capabilities with DEXASCAN's extensive network of over 400 testing locations, this collaboration seeks to provide a comprehensive approach to preventive health management.

Bridging the Gap in Healthcare

As modern healthcare increasingly generates substantial amounts of data, it often lacks the framework to translate that information into actionable insights for patients. Brett Hudson, Zyndio's Founder and CEO, emphasizes that the initiative aims to connect measurement with meaningful actions in clinical settings. He stated, "Healthcare has become excellent at generating data, but patients often struggle to understand what that information means and what to do next." Thus, the From Scan to Plan initiative focuses on creating a holistic, continuous care experience for patients working alongside their healthcare providers.

The DEXA Advantage

At the core of this collaboration is the Dual-Energy X-ray Absorptiometry (DEXA) scanning process, which offers detailed insights into an individual's body composition, including metrics on fat mass, lean mass, and bone density. This form of analysis not only informs about current body composition but also serves as a baseline for future health assessments. Tony Orlando, the founder of DEXASCAN.COM, acknowledges that patients frequently ask, "Now what?" after receiving their scan results, and this partnership aims to provide conclusive answers and actionable plans.

Specific Applications in GLP-1 Care

A particularly exciting aspect of this collaboration involves its potential application in monitoring body composition among patients undergoing GLP-1 treatment under medical supervision. The plan outlines a patient journey that includes initial assessments, physician evaluations, ongoing monitoring, and follow-up scans conducted at appropriately scheduled intervals. Zyndio's exploration of anticipatory milestones—90, 180, and 365 days—provides a structured timeline for patient treatment that prioritizes both care and follow-up.

Creating a Connected Health Ecosystem

Through this partnership, Zyndio envisions developing a robust ecosystem that not only connects diagnostic findings but also integrates laboratory biomarkers and related wearable data into clinical care. Matthew Trainer, Zyndio's Chief Technology Officer, remarked, "Healthcare doesn't have a shortage of data. It has a shortage of connections between the dots." By leveraging advanced AI technologies, Zyndio aims to create pathways that facilitate a comprehensive understanding of health trajectories, helping to guide both patients and physicians toward informed decisions.

Future Directions and Patient Engagement

As Zyndio and DEXASCAN embark on this exciting journey, there are plans to establish a clear implementation framework for patient engagement, exchanging information effectively, and coordinating clinical care. While the proposed integrations and care pathways are still in development, the commitment to empowering patients through enhanced communication and connectivity remains at the forefront of their mission.

About the Companies

Zyndio's mission centers on connecting eligible U.S. adults with licensed medical providers, ensuring that regulated treatments involve comprehensive clinical evaluations. With a focus on preventive health, Zyndio aims to blend diagnostics with continuous health monitoring to advance patient care.

On the other hand, DEXASCAN specializes in offering consumers direct access to body composition testing through a nationwide network of providers. The organization's offerings include DEXA body composition tests, bone density assessments, and other related measurements, each pivotal for creating a strategic health plan tailored to individual needs.

In conclusion, the collaboration between Zyndio and DEXASCAN marks a significant advancement in health technology and patient care, promising to enhance the usability of health data for better outcomes.